JP2023552851A5 - - Google Patents

Info

Publication number
JP2023552851A5
JP2023552851A5 JP2023535529A JP2023535529A JP2023552851A5 JP 2023552851 A5 JP2023552851 A5 JP 2023552851A5 JP 2023535529 A JP2023535529 A JP 2023535529A JP 2023535529 A JP2023535529 A JP 2023535529A JP 2023552851 A5 JP2023552851 A5 JP 2023552851A5
Authority
JP
Japan
Prior art keywords
chain
seq
antibody
cancer
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023535529A
Other languages
English (en)
Japanese (ja)
Other versions
JP7818838B2 (ja
JP2023552851A (ja
Filing date
Publication date
Priority claimed from CN202011427863.9A external-priority patent/CN113135996A/zh
Application filed filed Critical
Publication of JP2023552851A publication Critical patent/JP2023552851A/ja
Publication of JP2023552851A5 publication Critical patent/JP2023552851A5/ja
Application granted granted Critical
Publication of JP7818838B2 publication Critical patent/JP7818838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023535529A 2019-12-09 2021-05-19 二重特異性抗体およびその適用 Active JP7818838B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911253241 2019-12-09
CN202011427863.9A CN113135996A (zh) 2019-12-09 2020-12-09 一种双特异抗体及其应用
CN202011427863.9 2020-12-09
PCT/CN2021/094672 WO2022121239A1 (zh) 2019-12-09 2021-05-19 一种双特异性抗体及其应用

Publications (3)

Publication Number Publication Date
JP2023552851A JP2023552851A (ja) 2023-12-19
JP2023552851A5 true JP2023552851A5 (cg-RX-API-DMAC7.html) 2024-01-15
JP7818838B2 JP7818838B2 (ja) 2026-02-24

Family

ID=76809347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535529A Active JP7818838B2 (ja) 2019-12-09 2021-05-19 二重特異性抗体およびその適用

Country Status (5)

Country Link
US (1) US20240043567A1 (cg-RX-API-DMAC7.html)
EP (1) EP4261231A4 (cg-RX-API-DMAC7.html)
JP (1) JP7818838B2 (cg-RX-API-DMAC7.html)
CN (1) CN113135996A (cg-RX-API-DMAC7.html)
WO (1) WO2022121239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110054701B (zh) * 2019-04-17 2022-12-27 中国医学科学院血液病医院(血液学研究所) 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AU2022261268A1 (en) * 2021-04-22 2023-11-16 Guangdong Fapon Biopharma Inc. Bispecific multifunctional fusion polypeptide
US20240294640A1 (en) * 2021-06-02 2024-09-05 Qure Biotechnology (Shanghai) Co., Ltd. Anti-cd3 antibody variant, fusion protein, and application
US20250206823A1 (en) * 2021-07-30 2025-06-26 Qure Biotechnology (Shanghai) Co., Ltd. Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof
CN116284430A (zh) * 2021-07-30 2023-06-23 广东菲鹏制药股份有限公司 靶向肿瘤的il15融合蛋白及其应用
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
CN113817065B (zh) * 2021-09-06 2023-04-18 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
WO2023036270A1 (zh) * 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023046093A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物
WO2023046116A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种白介素15及其受体的多肽复合物
CN116262786B (zh) * 2021-12-13 2026-05-15 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
CN116496408A (zh) * 2022-01-21 2023-07-28 广东菲鹏制药股份有限公司 白细胞介素21及其受体复合物
CN115246885B (zh) * 2022-06-30 2023-10-24 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
WO2026114362A1 (zh) * 2024-11-29 2026-06-04 正大天晴药业集团股份有限公司 抗体-偶联物、其制备方法及应用
CN119775429B (zh) * 2024-12-26 2026-08-07 南开大学 一种抗人her2/ccr4的双特异性抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
JP6510532B2 (ja) * 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性her2抗体及び使用方法
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
US10905743B2 (en) * 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
EP3464352B1 (en) * 2016-05-27 2021-03-24 Altor BioScience Corporation Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CN117843810A (zh) * 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
KR20210003814A (ko) * 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204646A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
US20220143178A1 (en) * 2019-02-03 2022-05-12 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-her2 bispecific antibody and application thereof
JP7621263B2 (ja) * 2019-02-22 2025-01-24 武▲漢▼友芝友生物制▲薬▼股▲ふん▼有限公司 改変されたFc断片、それを含む抗体、及びそれらの使用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用

Similar Documents

Publication Publication Date Title
JP7818838B2 (ja) 二重特異性抗体およびその適用
US12269885B2 (en) Anti-PD-L1/VEGF bifunctional antibody and use thereof
KR102629503B1 (ko) TGF-β 수용체를 함유하는 융합 단백질 및 이의 약학적 용도
US11292841B2 (en) Anti-PD-1 nano-antibody and application thereof
CN105121474B (zh) 融合免疫调节蛋白及其制备方法
EP4406965A1 (en) Interleukin-2 mutant and fusion protein thereof
WO2018233574A1 (zh) 一种抗pd-l1人源化纳米抗体及其应用
CN109575140A (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
WO2023046156A1 (en) Il-2 variants and fusion proteins thereof
JP7766672B2 (ja) TGF-β RII突然変異体及びその融合タンパク質
CN114195894B (zh) 一种靶向4-1bb的抗体及其应用
JP2023526448A (ja) ヒトil-15変異体およびその使用
WO2021219127A1 (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
CA3134006A1 (en) Multispecific agents for treatment of cancer
AU2023205911A1 (en) Gamma delta t-cell-binding polypeptides and uses thereof
CN121554592A (zh) 靶向c-Met的多特异性抗体
CN103172741B (zh) 全人源抗egfr抗体
CN115246885A (zh) 一种双特异性抗体及其应用
CN115181180B (zh) 抗人程序性死亡配体-1(pd-l1)的抗体及其应用
WO2024199458A1 (en) Il-2 variants with improved stability and compositions thereof
KR20130057959A (ko) 항 her2 단일클론항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
CN118894943A (zh) 靶向密蛋白的双特异性抗体
CN118894944A (zh) 抗密蛋白双特异性抗体
HK40060665A (en) Anti-pd-l1/vegf bifunctional antibody and use thereof